Autoinjectors Market Key Competitors Overview: AbbVie Inc., Mylan, Eli Lilly and Company, Ypsomed, Amgen, Becton, Dickinson and Company, GlaxoSmithKline plc

The Autoinjectors Market report includes a range of inhibitors as well as driving forces of the market which are analyzed in both qualitative and quantitative approach so that readers and users get precise information and insights about the industry. Here, the market overview is given in terms of drivers, restraints, opportunities, and challenges where each of these parameters is studied scrupulously. Autoinjectors Market research report is generated with the best and advanced tools of collecting, recording, estimating, and analysing market data. Being a wide-ranging market research report, it is sure to help develop business in several ways.

The study of Autoinjectors Market report helps businesses to define their own strategies about the development in the existing product, modifications to consider for the future product, sales, marketing, promotion, and distribution of the product in the existing and new market. The research and analysis performed in this market report with faithful knowledge provide businesses a clear idea of what is already available, what the market expects, the competitive environment, and what can be done to outshine the competitor. This Autoinjectors Market research report also helps businesses to understand the various drivers and restraints impacting the market during the forecast period.

Request for FREE Sample Report: To Know the Impact of COVID-19 on this Industry @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=1592468

Some of the key players in the autoinjectors market are

AbbVie Inc. (US),
Mylan (US),
Eli Lilly and Company (US),
Ypsomed (Switzerland),
Amgen (US),
Becton, Dickinson and Company (US),
GlaxoSmithKline plc (UK),
Johnson & Johnson (US),
Teva Pharmaceutical (Israel),
Antares Pharma (US),
Merck KGaA (Germany),
Meridian Medical Technologies, Inc. (US),
Roche Diagnostics (Switzerland),
Bespak (UK),
Bayer (Germany),
SHL Medical (Switzerland),
Haselmeier (Switzerland),
Owen Mumford (UK),
Ravimed (Poland),
Medeca Pharma AB (Sweden),
Cambridge Consultants Ltd. (UK),
Flex (US),
SMC Ltd. (US),
and Promius Pharma (US).

Autoinjectors Market is the first-class market research report that conducts industry analysis on products, markets, companies, industries and many countries worldwide. The report analyses market information related to specific stock, currency, commodity and geographic region or country. This report deals with numerous parameters in detail to suit the requirements of business or clients. These parameters range from latest trends, market segmentation, new market entry, industry forecasting, target market analysis, future directions, opportunity identification, strategic analysis, insights to innovation. All of these are estimated and analyzed by a team of innovative, enthusiastic and motivated researchers and analysts so that nothing lefts uncovered in the Autoinjectors Market analysis report.

The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025. Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favorable reimbursements and government support, and technological advancements. The patent expiry of biologics is also expected to provide growth opportunities for players in the market.

The study includes an in-depth competitive analysis of these key players in the autoinjectors market, along with their company profiles, recent developments, and key market strategies.

On the other hand, the preference for alternative routes of drug delivery such as oral diabetic agents and nasal epinephrine sprays is expected to limit the adoption of autoinjector devices.

“The rheumatoid arthritis segment accounted for the largest share of the autoinjectors market in 2020”

Based on therapy, the autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, and other therapies (cardiovascular diseases, migraine treatment, anemia, and progesterone therapy). In 2019, rheumatoid arthritis accounted for the largest market share of autoinjectors market. The large share of this segment is mainly due to the high prevalence of rheumatoid arthritis.

“The subcutaneous segment is projected to grow at the highest CAGR during the forecast period”

Based on route of administration, the autoinjectors market is segmented into intramuscular and subcutaneous. Patients use autoinjectors for intramuscular and subcutaneous administration of various drugs for the treatment of diseases such as rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, migraine, anemia, and cancer. The subcutaneous segment is projected to grow at the highest CAGR during the forecast period. The highest CAGR of this segment can primarily be attributed to the growing number of product approvals by regulatory bodies for the treatment of chronic diseases.

“North America accounted for the largest share of the autoinjectors market in 2020.”

The autoinjectors market is segmented into five major regions, namely, Europe, North America, the Asia Pacific, Latin America, and the Middle East & Africa. North America was the largest regional market for autoinjectors. Growth in the North American market is majorly driven by factors such as the rising incidence of anaphylaxis and the presence of favorable reimbursements. Moreover, the US and Canada are developed economies with high awareness and adoption rates for advanced devices such as autoinjectors, which is beneficial for market growth. Furthermore, other microeconomic indicators such as rising healthcare expenditures, high affordability rate, and the improving regulatory scenario are also major factors contributing to market growth.

By Company: Tier 1: 40%, Tier 2: 35%, and Tier 3: 25%
By Designation: C-level Executives: 25%, Directors: 55%, and Others: 20%
By Region: North America: 40%, Europe: 25%, APAC: 20%, LATAM: 10% and MEA: 5%

Enquire Here for, Report Enquiry, Discount and Customization @ https://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1592468

Research Coverage:

The market study covers the autoinjectors market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by therapy, type, route of administration, end users and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants in this market and provide information regarding the closest approximations of the autoinjectorsmarket and its sub segments. This report will help stakeholders understand the competitive landscape, gain insights to position their businesses better, and plan suitable go-to-market strategies. The report will also help stakeholders understand the pulse of the market and provide information on key market drivers, restraints, opportunities and challenges.

Table Of Contents

1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition & Scope
1.3 Markets Covered
Figure 1 Autoinjectors Market Segmentation
1.4 Years Considered For The Study
1.5 Currency
1.6 Limitations
1.7 Stakeholders
1.8 Summary Of Changes

2 Research Methodology
2.1 Research Approach
Figure 2 Research Design
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Breakdown Of Primaries
Figure 4 Breakdown Of Primary Interviews (Supply Side): By Company Type, Designation, And Region
Figure 5 Breakdown Of Primary Interviews (Demand Side): By End User, Designation, And Region
2.2 Market Size Estimation
Figure 6 Market Size Estimation: Revenue Share Analysis (2019)
Figure 7 Market Size Estimation: Revenue Share Analysis (2019)
Figure 8 Supply-Side Analysis: Autoinjectors Market (2019)
Figure 9 Cagr Projections: Supply-Side Analysis Of The Autoinjectors Market (2019)
Figure 10 Cagr Projections From The Analysis Of Drivers, Restraints, Opportunities, And Challenges Of The Autoinjectors Market (2020–2025)
2.3 Market Breakdown & Data Triangulation
2.4 Market Share Estimation
2.5 Assumptions For The Study
2.6 Covid-19 Health Assessment
2.7 Covid-19 Economic Assessment
2.8 Assessment Of The Impact Of Covid-19 On The Economic Scenario
Figure 12 Criteria Impacting The Global Economy
Figure 13 Recovery Scenario Of The Global Economy

3 Executive Summary
Figure 14 Autoinjectors Market, By Therapy, 2020 Vs. 2025 (Usd Million)
Figure 15 Autoinjectors Market, By Type, 2020 Vs. 2025 (Usd Million)
Figure 16 Autoinjectors Market, By Route Of Administration, 2020 Vs. 2025 (Usd Million)
Figure 17 Autoinjectors Market, By End User, 2020 Vs. 2025 (Usd Million)
Figure 18 Geographical Snapshot Of The Autoinjectors Market

4 Premium Insights
4.1 Autoinjectors Market Overview
Figure 19 Growing Prevalence Of Targeted Therapies And Rising Preference For Self-Administration Of Drugs To Drive Market Growth
4.2 Asia Pacific: Autoinjectors Market, By Therapy And Country (2020)
Figure 20 Rheumatoid Arthritis Segment To Account For The Largest Share Of The Apac Market In 2020
4.3 Autoinjectors Market, By Region, 2020−2025
Figure 21 North America Will Continue To Dominate The Autoinjectors Market In The Forecast Period
4.4 Autoinjectors Market: Developed Vs. Developing Markets
Figure 22 Developing Markets To Register Higher Growth During The Forecast Period

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
Figure 23 Autoinjectors Market: Drivers, Restraints, Opportunities, & Challenges
5.2.1 Drivers
5.2.1.1 Growing Prevalence Of Targeted Therapies
Figure 24 China: Total Diabetic Population From 2010 To 2045
5.2.1.2 Rising Incidence Of Anaphylaxis
5.2.1.3 Increasing Number Of Regulatory Approvals
Table 1 Recent Approvals Of Autoinjector Devices Across The Globe
5.2.1.4 Availability Of Generic Versions Of Autoinjectors
5.2.1.5 Favorable Reimbursements And Government Support
5.2.1.6 Ease Of Use Increasing The Preference For Self-Administration
5.2.2 Restraints
5.2.2.1 Alternative Drug Delivery Modes
5.2.2.2 Research, Development, And Launch Of Oral Diabetic Agents And Oral Insulin
5.2.2.3 Development Of Nasal Epinephrine Sprays
5.2.3 Opportunities
5.2.3.1 Patent Expiry Of Biologics To Drive The Demand For Biosimilars
Table 2 Patent Expiry Of Key Biologics
5.2.3.2 Need To Limit Patient Visits And Physical Contact
5.2.4 Challenges
5.2.4.1 Development Of Autoinjectors For Multiple Drug Viscosities
5.2.4.2 Lack Of Proper Training For Using Autoinjectors
5.3 Covid-19 Impact On The Autoinjectors Market
5.4 Average Selling Price Trends
Table 3 Average Selling Price Of Epinephrine Autoinjectors, By Region, 2015 Vs. 2020
5.5 Value Chain Analysis
Figure 25 Autoinjectors Market: Value Chain Analysis (2019)
5.6 Ecosystem Analysis
Figure 26 Ecosystem: Autoinjectors Market (2019)

6 Industry Insights
6.1 Introduction
6.2 Industry Trends
6.2.1 Advancements In Autoinjector Design
6.2.2 Wearable Autoinjectors
6.2.3 Connected Autoinjector Devices

7 Autoinjectors Market, By Therapy
7.1 Introduction
Table 4 Autoinjectors Market, By Therapy, 2018–2025 (Usd Million)
7.2 Rheumatoid Arthritis
7.2.1 Increasing Incidence Of Ra Has Boosted The Adoption Of Autoinjectors
Table 5 Autoinjectors Market For Rheumatoid Arthritis, By Country, 2018–2025 (Usd Million)
7.3 Diabetes
7.3.1 Large Patient Population To Stimulate The Demand For Autoinjectors During The Forecast Period
Figure 27 Diabetic Population: Top Countries/Territories (20–79 Years), 2019 Vs. 2030 Vs. 2045
Table 6 Autoinjectors Market For Diabetes, By Country,2018–2025 (Usd Million)
7.4 Multiple Sclerosis
7.4.1 Influx Of Generics Is Expected To Negatively Impact Market Growth During The Forecast Period
Figure 28 Number Of People With Ms (Per 100,000) - Who Regions
Table 7 Autoinjectors Market For Multiple Sclerosis, By Country, 2018–2025 (Usd Million)
7.5 Anaphylaxis
7.5.1 Increasing Prevalence Of Food Allergies To Drive The Uptake Of Autoinjectors
Table 8 Autoinjectors Market For Anaphylaxis, By Country,2018–2025 (Usd Million)
7.6 Other Therapies
Table 9 Autoinjectors Market For Other Therapies, By Country, 2018–2025 (Usd Million)
7.7 Impact Of Covid-19 On The Therapeutic Applications Of Autoinjectors

8 Autoinjectors Market, By Type
8.1 Introduction
Table 10 Comparison Of Disposable & Reusable Autoinjectors
Table 11 Autoinjectors Market, By Type, 2018–2025 (Usd Million)
8.2 Disposable Autoinjectors
8.2.1 Disposable Autoinjectors Are Convenient For Patients With Reduced Dexterity Or Visual Impairments
Table 12 Disposable Autoinjectors Market, By Country, 2018–2025 (Usd Million)
8.3 Reusable Autoinjectors
8.3.1 Reusable Autoinjectors Are More Economical As Compared To Disposable Autoinjectors
Table 13 Reusable Autoinjectors Market, By Country,2018–2025 (Usd Million)

9 Autoinjectors Market, By Route Of Administration
9.1 Introduction
Table 14 Autoinjectors Market, By Route Of Administration,2018–2025 (Usd Million)
9.2 Subcutaneous
9.2.1 Growing Number Of Product Approvals By Regulatory Bodies Will Support The Growth Of This Market Segment
Table 15 Subcutaneous Autoinjectors, By Country, 2018–2025 (Usd Million)
9.3 Intramuscular
9.3.1 Intramuscular Route Of Administration Enables Medication To Be Absorbed Quickly—A Key Factor Driving Market Growth
Table 16 Examples Of Intramuscular Autoinjectors
Table 17 Intramuscular Autoinjectors Market, By Country, 2018–2025 (Usd Million)

10 Autoinjectors Market, By End User
10.1 Introduction
Table 18 Autoinjectors Market, By End User, 2018–2025 (Usd Million)
10.2 Home Care Settings
10.2.1 Home Care Therapies Are Cost-Effective Compared To Treatments In Hospitals—A Key Factor Driving Market Growth
Table 19 Autoinjectors Market For Home Care Settings, By Country, 2018–2025 (Usd Million)
10.3 Hospitals & Clinics
10.3.1 High Usage Of Autoinjectors In Emergency Cases In Hospitals & Clinics Will Drive Market Growth
Table 20 Autoinjectors Market For Hospitals & Clinics, By Country, 2018–2025 (Usd Million)
10.4 Ambulatory Care Settings
10.4.1 Increasing Number Of Patients In Ambulatory Care Settings To Drive The Demand For Autoinjectors
Table 21 Autoinjectors Market For Ambulatory Care Settings, By Country, 2018–2025 (Usd Million)

11 Autoinjectors Market, By Region

Read More..................

Purchase the Report Directly @ https://www.reportsnreports.com/purchase.aspx?name=1592468

Contact Us:

Corporate Headquarters
Tower B5, office 101,
Magarpatta SEZ,
Hadapsar, Pune-411013, India
+ 1 888 391 5441
sales@reportsandreports.com

About Us:

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

This release was published on openPR.